Understanding and precision targeting of malfunctioning gene regulatory elements in human cancer and other enhanceropathies
Understanding and precision targeting of malfunctioning gene regulatory elements in human cancer and other enhanceropathies
The Precision Cancer Epigenomics laboratory at NCMM (Nordic-EMBL Partnership Institute) at the University of Oslo, Norway started in September 2022.
The Enhancer Biology lab started in June 2019 in the Applied Tumor Genomics research program of the Faculty of Medicine at the University of Helsinki, Finland.
We have a total of 10 group members in both our Oslo and Helsinki groups, lead by Dr Biswajyoti Sahu, and we are looking forward to grow in the coming days!
Our goal is to understand the molecular mechanisms of chromatin reprogramming by transcription factors in cell fate control and in cancer and human enhanceropathies.
We use state-of-the-art genomics methods for transcription factor binding, functional enhancer activity, chromatin accessibility and genome editing by CRISPR-Cas9.
We employ computational tools to analyse and integrate genome wide datasets from several multiomics methods utilising next-generation sequencing.
We use novel cell fate conversion methods to study the early regulatory events in pancreatic cancer – one of the most lethal cancer types currently lacking clear diagnostic markers and effective treatment options.
Our goal is to understand the human regulatory elements in enhancer reprogramming and malfunction using a plethora of functional genomics methods in several cancer types of endodermal lineage.
To understand the epigenome reprogramming events during disease progression, we are using hospital biobank samples for prostate cancer and innovative cell-based models for delineating the molecular causes of endometriosis.
To achieve our research objectives, we utilize various cutting-edge genome-wide techniques based on next generation sequencing and their computational analysis from bulk samples to single cell and single molecule resolution.
I lead the Precision Cancer Epigenomics laboratory in Oslo and the Enhancer Biology laboratory in Helsinki. I am genomics scientist by training and the primary goal of my research is to understand the role of transcription factors and the non-coding regulatory genome in human enhanceropathies such as cancer.
I am a Group Leader in Centre for Molecular Medicine (NCMM, Nordic-EMBL Partnership Institute) of the Faculty of Medicine at the University of Oslo, Norway and also hold an Adjunct Researcher position at the Oslo University Hospital in the Department of Cancer Genetics at the Institute of Cancer Research in Norway.
I am also a Principal Investigator at the Applied Tumor Genomics program of the Research Programs Unit at the Faculty of Medicine, University of Helsinki, Finland. I also hold the title of Docent in Molecular Genetics from the University of Helsinki, Finland.
Transposable elements (TEs) have emerged as important factors in establishing the cell type-specific gene regulatory networks and evolutionary novelty of embryonic and placental development.
Ectopic expression of lineage-specific transcription factors (TFs) of another cell type can induce cell fate reprogramming. However, the heterogeneity of reprogramming cells has been a challenge for data interpretation and model evaluation.
The combination of immunotherapy and epigenetic therapy is emerging as a promising approach for cancer therapy. Epigenetic therapy can induce derepression of transposable elements (TEs) that play a major role in activation of immune response against cancer cells.
If you’d like to get in touch, please use the contact form, call us by phone or visit our lab in Oslo or Helsinki.
Feel free to contact us about possible collaboration opportunities! We are always looking for motivated researchers!!
Master’s thesis students who are interested in bioinformatics and computational analysis of NGS and single-cell omics datasets can always contact us about available thesis projects and positions.
STIFTELSEN ASTRI OG BIRGER TORSTEDS LEGATER
Precision targeting of malfunctioning gene regulatory elements in human cancer and other enhanceropathies.
About us
Site info
